Response to a letter from J-P Chippaux and L Boyer entitled: "The 3 + 3 dose escalation design is not appropriate for antivenom dose finding."

Toxicon

Volumn 55, Issue 7, 2010, Pages 1410-1411

  Habib, Abdulrazaq G ^a   Nasidi, Abdulsalami ^a   Alder, Nicola ^a   Juszczak, Edmund ^a   Theakston, R David G ^a   Warrell, David A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; SNAKE VENOM ANTISERUM;

ANAPHYLAXIS; BLEEDING; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENVENOMATION; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INTRACUTANEOUS TEST; LETTER; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; PRURITUS; RESEARCH ETHICS; RESEARCH SUBJECT; RISK FACTOR; TOTAL QUALITY MANAGEMENT; URTICARIA;

EID: 77951653064     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2010.02.013     Document Type: Letter

References (12)

1. Bailey B., McGuigan M.A. Management of anaphylactoid reactions to intravenous N-acetylcysteine. Ann. Emerg. Med. 1998 Jun, 31(6):710-715.
2. Cardoso J.L., Fan H.W., França F.O., et al. Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in São Paulo, Brazil. Q. J. Med. 1993 May, 86(5):315-325.
3. Chippaux J.P., Lang J., Eddine S.A., et al. Clinical safety of a polyvalent F(ab')2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. Trans. R. Soc. Trop. Med. Hyg. 1998 Nov-Dec, 92(6):657-662. VAO (Venin Afrique de l'Ouest) Investigators.
4. Chippaux J.P., Lang J., Amadi-Eddine S., et al. Short report: treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab)2: results of a clinical trial in northern Cameroon. Am. J. Trop. Med. Hyg. 1999 Dec, 61(6):1017-1018.
5. Chippaux J.P., Massougbodji A., Stock R.P., Alagon A. Investigators of African antivipmyn in Benin. Clinical trial of an F(ab')2 polyvalent equine antivenom for African snake bites in Benin. Am. J. Trop. Med. Hyg. 2007 Sep, 77(3):538-546.
6. Cupo P., Azevedo-Marques M.M., Menezes J.B., Hering S.E. Reações es de hipersensibilidade imediatas após uso intravenoso de soros antivenenos: valor prognóstico dos testes de sensibilidade intradérmicos. Rev. Inst. Med. Trop. São Paulo 1991, 33:115-122.
7. Clinical Aspects of Immunology 1963, Blackwell, Oxford, England. first ed. P.G.H. Gell, R.R.A. Coombs (Eds.).
8. Johansson S.G., Bieber T., Dahl R., et al. Revised nomenclature for allergy for global use: report of the nomenclature review committee of the world allergy organization, october 2003. J. Allergy Clin. Immunol. 2004 May, 113(5):832-836.
9. Malasit P., Warrell D.A., Chanthavanich P., et al. Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. Br. Med. J. 1986 Jan 4, 292(6512):17-20. (Clin Res Ed).
10. Reid H.A. Antivenom reactions and efficacy. Lancet 1980 May 10, 1(8176):1024-1025.
11. St Clair E.W. The calm after the cytokine storm: lessons from the TGN1412 trial. J. Clin. Invest. 2008 Apr, 118(4):1344-1347.
12. World Health Organisation Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins 2010, WHO, Geneva.